List of Excipients in Branded Drug ELYXYB

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
BioDelivery Sciences International Inc	ELYXYB - CELECOXIB	celecoxib	59385-055	ACESULFAME POTASSIUM
BioDelivery Sciences International Inc	ELYXYB - CELECOXIB	celecoxib	59385-055	ALCOHOL
BioDelivery Sciences International Inc	ELYXYB - CELECOXIB	celecoxib	59385-055	AMMONIUM GLYCYRRHIZATE

Elyxyb Excipient Strategy and Commercial Opportunities

Last updated: September 8, 2026

Elyxyb is a prescription celecoxib oral solution for the acute treatment of migraine with or without aura in adults. Its principal commercial differentiation is a liquid, ready-to-use dosage form containing 25 mg/mL celecoxib, rather than a conventional solid oral capsule. The formulation uses glycerin, povidone, sucralose, sodium benzoate, peppermint flavor, and water, according to the FDA-approved labeling.[1]

The strongest commercial opportunities are migraine patients who have difficulty swallowing tablets, need dose flexibility, or prefer a liquid product. The main development risks are formulation equivalence, celecoxib solubility, taste masking, dose-volume acceptability, packaging compatibility, and generic substitution.

What is Elyxyb and how does its formulation differ from celecoxib capsules?

Elyxyb contains celecoxib, a selective cyclooxygenase-2 inhibitor. It is indicated for adults with acute migraine, with or without aura. The recommended dose is 120 mg, equivalent to 4.8 mL of the 25 mg/mL oral solution.[1]

Attribute	Elyxyb	Conventional celecoxib capsules
Active ingredient	Celecoxib	Celecoxib
Dosage form	Oral solution	Capsule
Strength	25 mg/mL	Commonly 50, 100, 200 and 400 mg capsules
Approved use	Acute migraine in adults	Multiple pain and inflammatory conditions, depending on labeling
Standard acute dose for Elyxyb	120 mg	Product- and indication-specific
Dose volume	4.8 mL	One or more capsules
Administration	Direct oral dosing	Swallowing solid dosage form
Product type	Prescription small-molecule drug	Prescription small-molecule drug

Elyxyb is not a new chemical entity. Its commercial value depends on dosage-form differentiation, migraine positioning, patient usability, and protection of the liquid formulation rather than on chemical-entity exclusivity.

Which excipients are used in Elyxyb?

The labeled inactive ingredients are glycerin, povidone, sucralose, sodium benzoate, peppermint flavor, and water.[1]

Excipient	Likely formulation role	Commercial or technical relevance
Glycerin	Solvent, cosolvent, humectant, mouthfeel modifier	Supports liquid handling and may improve palatability
Povidone	Solubilizer, wetting aid, viscosity and physical-stability aid	Can help maintain celecoxib dispersion or solution uniformity
Sucralose	High-intensity sweetener	Masks celecoxib bitterness
Peppermint flavor	Flavor system	Reduces residual bitterness and improves patient acceptability
Sodium benzoate	Preservative	Supports microbiological control in an aqueous multidose formulation
Water	Primary vehicle	Enables direct oral liquid administration

The excipient system is commercially efficient because it uses familiar pharmaceutical and food-compatible materials instead of a more complex delivery platform such as a lipid system, nanocrystal suspension, or cyclodextrin complex.

Why is celecoxib a difficult molecule for liquid formulation?

Celecoxib has low aqueous solubility. A 25 mg/mL liquid therefore requires a formulation strategy that maintains adequate drug solubilization or physical uniformity at the labeled concentration.

The development challenge is not limited to dissolving celecoxib during manufacture. The finished product must maintain:

• Content uniformity across the bottle or dose;
• Chemical stability over shelf life;
• Physical stability without precipitation or crystal growth;
• Acceptable viscosity for accurate dosing;
• Palatable taste at a 120 mg dose;
• Compatibility with the bottle, cap, measuring device, and label;
• Microbiological quality after opening, if supplied as a multidose product.

Povidone and glycerin are central to the formulation strategy. Povidone can improve wetting and drug-excipient interactions, while glycerin contributes to solvent capacity and mouthfeel. The sweetener and flavor system address the practical problem that celecoxib can produce a bitter or lingering taste at therapeutic dose levels.

What formulation patents protect Elyxyb?

Public product information identifies Elyxyb as NDA 213426, but the FDA-approved label does not provide a complete freedom-to-operate analysis for the formulation.[1] Formulation protection may include claims directed to:

• Celecoxib liquid compositions;
• Concentration ranges near 25 mg/mL;
• Specific combinations of glycerin, povidone, sweetener, flavor, preservative, and water;
• Stability and precipitation control;
• Methods of treating acute migraine with a celecoxib oral solution;
• Packaging or dosing systems associated with the liquid product.

Patent scope must be assessed claim by claim. A patent covering a broad celecoxib liquid may be vulnerable to prior-art challenges, while a narrower claim directed to a specific excipient ratio, stability profile, or manufacturing sequence may provide stronger protection if supported by comparative data.

For an abbreviated generic applicant, the principal question is whether the proposed product can avoid the relevant formulation and method-of-use claims while still meeting pharmaceutical equivalence and bioequivalence requirements.

When does Elyxyb lose exclusivity?

Elyxyb’s exclusivity profile has several components:

Exclusivity element	Relevance to Elyxyb
New chemical entity exclusivity	Generally unavailable because celecoxib was previously approved
New dosage form	May support regulatory exclusivity in limited circumstances, but not the full NCE period
New indication	May support three-year exclusivity if statutory requirements are met
Formulation patents	May delay or complicate generic launch if valid and enforceable
Method-of-use patents	May restrict labeled migraine use but may not block all off-label or carve-out strategies
Regulatory exclusivity	Depends on the approval basis and FDA-recognized exclusivity periods

FDA approval occurred in 2020.[1] The commercial loss-of-exclusivity date cannot be determined from the approval year alone. It depends on the current Orange Book record, listed patents, pediatric exclusivity, regulatory exclusivity, and any litigation settlements.

A generic applicant could pursue an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. A 505(b)(2) pathway could be relevant for a materially different celecoxib liquid, but an ANDA is the more direct route for a therapeutically equivalent copy of the listed oral solution.

What is the Orange Book status of Elyxyb?

Elyxyb is an FDA-approved prescription product associated with NDA 213426.[1] The Orange Book is the controlling source for current patent listings, exclusivity codes, and therapeutic-equivalence information.[2]

The practical commercial questions are:

1. Whether Elyxyb is listed as the reference listed drug for an oral-solution product.
2. Whether formulation patents are listed against the NDA.
3. Whether method-of-use patents cover acute migraine treatment.
4. Whether any listed patents have expiration dates that extend beyond regulatory exclusivity.
5. Whether a generic applicant has filed a Paragraph IV certification.

A Paragraph IV challenge would create patent litigation risk if a generic applicant alleges that listed patents are invalid, unenforceable, or not infringed. The patent holder could obtain a 30-month stay of FDA approval under the Hatch-Waxman framework, subject to statutory exceptions and litigation developments.[3]

No biosimilar pathway applies. Celecoxib is a synthetic small molecule, and Elyxyb is not a biologic. Competitive entry would occur through an ANDA or, for a materially differentiated product, potentially a 505(b)(2) application.

What generic entry risks exist for Elyxyb?

The principal generic risks are formulation substitution and indication-driven market erosion.

Formulation equivalence

A generic oral solution must match the reference product in active-ingredient concentration and meet applicable pharmaceutical-equivalence requirements. It may use different inactive ingredients if the product remains pharmaceutically equivalent, bioequivalent, stable, and acceptable under FDA requirements.

The key technical hurdles are:

• Demonstrating uniform celecoxib concentration;
• Controlling precipitation after storage;
• Matching absorption despite different excipient systems;
• Demonstrating preservative effectiveness;
• Managing taste differences;
• Establishing accurate dose delivery.

Taste is commercially important because a 4.8 mL dose places a relatively high celecoxib load in the mouth. A generic with acceptable bioequivalence but poor palatability could still lose patient preference in cash-pay, specialty-pharmacy, or prescriber-directed channels.

Carve-out and skinny-label risk

If method-of-use claims cover migraine, an ANDA applicant may attempt a labeling carve-out for protected uses. That approach can preserve approval for unprotected uses while limiting the generic label. Elyxyb’s narrow approved indication may reduce the commercial value of such a carve-out because acute migraine is the product’s primary labeled market.

Substitution risk

If FDA grants therapeutic equivalence to a generic oral solution, pharmacy-level substitution could reduce branded volume quickly. The risk is higher if the generic matches the 25 mg/mL concentration and uses a familiar oral dosing device.

How strong is the Elyxyb patent estate?

The commercial strength of the estate depends less on celecoxib itself than on the defensibility of the liquid formulation and the breadth of any migraine-use claims.

Protection layer	Relative strategic value
Celecoxib composition-of-matter patent	Low for Elyxyb because the molecule is mature
Broad oral-liquid patent	Moderate, but dependent on prior art and claim construction
Narrow excipient-combination patent	Potentially meaningful if supported by unexpected stability or bioavailability data
Specific concentration claims	Useful against close copies, but vulnerable to design-around
Method-of-use migraine claims	Potentially useful against labeled copies
Packaging and dosing claims	Usually supplemental rather than decisive
Manufacturing-process claims	Can raise cost and complexity for competitors, but may be difficult to enforce

The strongest estate would combine formulation claims with method-of-use claims and commercially difficult design-around options. An estate limited to a basic celecoxib liquid with conventional excipients would face greater invalidity and non-infringement risk.

What excipient strategies could create new commercial opportunities?

Pediatric and adolescent migraine

Elyxyb is labeled for adults. A liquid dosage form is naturally suited to patients who cannot swallow capsules, but expansion into pediatric migraine would require clinical, regulatory, and safety support. The formulation’s 25 mg/mL strength may require a lower-strength presentation or a validated dose-measuring device for weight-based dosing.

A 10 mg/mL or 12.5 mg/mL version could improve dosing flexibility, reduce measurement error, and support age-banded administration. Any new strength would require regulatory justification and could create additional formulation and packaging claims.

Dysphagia and geriatric use

A liquid celecoxib product can target adults with dysphagia, neurological disease, post-surgical swallowing limitations, or difficulty taking capsules. The opportunity is clinically plausible but commercially limited by the product’s acute-migraine label. Prescriber education and payer coverage would determine whether this population produces meaningful incremental demand.

Taste and mouthfeel improvements

Potential next-generation strategies include:

• More effective bitterness suppression;
• Reduced peppermint intensity;
• Lower viscosity for faster administration;
• Unit-dose sachets or stick packs;
• Smaller-volume concentrated dosing;
• Child-resistant packaging with an integrated oral syringe;
• Flavor variants for patient preference.

The best commercial improvements would preserve the current 25 mg/mL concentration while improving taste, portability, and dose accuracy.

Unit-dose packaging

A premeasured 4.8 mL unit dose could reduce dosing errors and improve portability for migraine patients. Single-use packaging also limits microbial exposure and may reduce the preservative burden. The tradeoff is higher packaging cost and greater filling precision requirements.

Combination therapy

A fixed or co-packaged migraine product combining celecoxib with an antiemetic, triptan, or other acute-migraine agent could create a differentiated regimen. A fixed-dose combination would require new clinical and regulatory work. A co-packaged product could be developed more quickly but would face separate reimbursement and intellectual-property analysis.

How does Elyxyb compare with competing acute-migraine products?

Product category	Key advantage	Key limitation relative to Elyxyb
Celecoxib capsules	Low-cost, familiar active ingredient	Solid dosage form and less convenient for dysphagia
Ibuprofen or naproxen tablets	Broad availability and low price	Nonselective NSAID profile and solid dosage form
Sumatriptan nasal spray	Nonoral administration	Triptan contraindications and tolerability issues
CGRP antagonists	Migraine-specific mechanisms and growing use	Higher cost and different access requirements
Oral dissolving products	Easier administration	Limited liquid-dose flexibility
Prescription oral solutions	Patient-friendly administration	Often higher manufacturing and packaging cost

Elyxyb’s commercial positioning is strongest where the liquid format changes patient behavior or solves a practical administration problem. It is weaker where prescribers and payers view celecoxib as interchangeable with inexpensive generic NSAIDs.

What revenue exposure and licensing opportunities exist?

The product’s revenue exposure is concentrated in branded acute-migraine prescriptions, payer coverage, and protection from generic substitution. The manufacturer is responsible for maintaining the regulatory and commercial platform, while exact Elyxyb product revenue has not been separately disclosed in the public financial reporting reviewed here.[4]

Potential licensing opportunities include:

• Regional commercialization rights;
• Pediatric development partnerships;
• Co-packaging with migraine therapies;
• Generic or authorized-generic arrangements;
• Excipient and taste-masking technology licenses;
• Contract manufacturing for unit-dose packaging;
• International registration of a celecoxib liquid product.

The most valuable licensing asset would be a formulation platform that improves celecoxib solubility while preserving a low excipient burden and acceptable taste. A formulation that supports multiple strengths, pediatric dosing, and unit-dose packaging would have greater partnering value than a single fixed-concentration product.

Key Takeaways

• Elyxyb is a 25 mg/mL celecoxib oral solution approved for acute migraine in adults.
• Its labeled excipients are glycerin, povidone, sucralose, sodium benzoate, peppermint flavor, and water.
• The core technical challenge is maintaining celecoxib solubility or uniformity while controlling taste, stability, and dose accuracy.
• The best commercial opportunities are unit-dose packaging, improved taste masking, pediatric development, dysphagia-focused positioning, and regional licensing.
• Generic risk will center on ANDA formulation equivalence, Paragraph IV challenges, method-of-use claims, and pharmacy substitution.
• Elyxyb has no biosimilar pathway because celecoxib is a synthetic small molecule.
• The Orange Book and current patent records control the operative exclusivity analysis; the 2020 approval date alone does not establish the final generic-entry date.

FAQs

Can Elyxyb be reformulated without povidone?

Yes. A competing product could use a different solubilization or stabilization system, provided it meets FDA requirements for quality, bioequivalence, stability, safety, and pharmaceutical equivalence. Removing povidone could alter precipitation behavior, viscosity, taste, and absorption.

Is Elyxyb suitable for pediatric migraine today?

The product is labeled for adults. Pediatric use would require an appropriate regulatory basis, dosing rationale, and supporting safety and efficacy data.

Could a generic Elyxyb use a different flavor?

Yes. Flavor is generally an inactive-ingredient attribute, but the alternative formulation must remain acceptable for safety, stability, manufacturing, and bioequivalence purposes. A different flavor could create a meaningful patient-preference difference without changing the active ingredient.

Does a generic capsule compete directly with Elyxyb?

Yes, but substitution depends on dosage form, therapeutic-equivalence status, prescription channel, payer policy, and patient ability to swallow capsules. A capsule is a commercial substitute for many adults but not for every patient targeted by the liquid format.

Is a 4.8 mL dose commercially convenient?

It is manageable with an oral syringe or calibrated dosing device. A premeasured 4.8 mL unit dose could improve portability and reduce measurement error, while a more concentrated formulation could reduce dose volume if stability and palatability remain acceptable.

References

1. U.S. Food and Drug Administration. (2020). Elyxyb (celecoxib) oral solution prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2018). Patent and exclusivity information.
4. Collegium Pharmaceutical, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.